Trial · NCT02341014

Combination Therapy With Carfilzomib, Romidepsin, Lenalidomide in Patients With Relapsed or Refractory B- and T-cell Lymphomas

NCT02341014, Phase 1, Phase 2, Completed, Memorial Sloan Kettering Cancer Center; results first posted 2024-04-04

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Combination Therapy With Carfilzomib, Romidepsin, Lenalidomide in Patients With Relapsed or Refractory B- and T-cell Lymphomas. Trials, record NCT02341014. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02341014

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Combination Therapy With Carfilzomib, Romidepsin, Lenalidomide in Patients With Relapsed or Refractory B- and T-cell Lymphomas
NCT number: NCT02341014
Status: Completed
Phases: Phase 1, Phase 2
Enrollment: 27 participants, actual
Lead sponsor: Memorial Sloan Kettering Cancer Center
Conditions: T-cell Lymphomas, Relapsed or Refractory
Interventions: Carfilzomib, Romidepsin, Lenalidomide
First posted: 2015-01-19
Last updated: 2024-04-04
Results first posted: 2024-04-04

Source ClinicalTrials.gov

Registered outcomes4

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Maximum Tolerated Dose of Romidepsin	21 days	Determine the MTD by NCI-CTCAE v4.0.
Primary	Maximum Tolerated Dose of Lenalidomide	21 days	Determine the MTD by NCI-CTCAE v4.0.
Primary	Maximum Tolerated Dose of Carfilzomib	21 days	Determine the MTD by NCI-CTCAE v4.0.
Secondary	Overall Response Rate (Orr) at the Maximum Tolerated Dose	1 year	will be summarized using percentages and confidence intervals will be provided. ORR will be calculated based on the best response at any time during the course of treatment on this protocol.

Source ClinicalTrials.gov

Outcomes4

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Maximum Tolerated Dose of Romidepsin	21 days	Phase Ib participants	mg/m^2 romidepsin	NUMBER
PRIMARY	Maximum Tolerated Dose of Lenalidomide	21 days	Phase Ib participants	mg of Lenalidomide	NUMBER
PRIMARY	Maximum Tolerated Dose of Carfilzomib	21 days	Phase Ib participants	mg/m^2 of Carfilzomib	NUMBER
SECONDARY	Overall Response Rate (Orr) at the Maximum Tolerated Dose	1 year	T-cell Lymphoma participants evaluable for response at the maximum tolerated dose	percentage of pts with response	NUMBER

Source ClinicalTrials.gov

Results by group9

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Value	Spread	Units
Maximum Tolerated Dose of Romidepsin	Phase Ib: DL 1	8		mg/m^2 romidepsin
Maximum Tolerated Dose of Romidepsin	Phase Ib: DL 2	8		mg/m^2 romidepsin
Maximum Tolerated Dose of Lenalidomide	Phase Ib: DL 1	15		mg of Lenalidomide
Maximum Tolerated Dose of Lenalidomide	Phase Ib: DL 2	15		mg of Lenalidomide
Maximum Tolerated Dose of Carfilzomib	Phase 1b: DL 1	36		mg/m^2 of Carfilzomib
Maximum Tolerated Dose of Carfilzomib	Phase 1b: DL 2	36		mg/m^2 of Carfilzomib
Overall Response Rate (Orr) at the Maximum Tolerated Dose	Phase 1b: DL 1	50	95% Confidence Interval 12 to 88	percentage of pts with response
Overall Response Rate (Orr) at the Maximum Tolerated Dose	Phase 1b: DL 2	57	95% Confidence Interval 18 to 90	percentage of pts with response
Overall Response Rate (Orr) at the Maximum Tolerated Dose	Phase IIa - MTD	42	95% Confidence Interval 15 to 72	percentage of pts with response

Source ClinicalTrials.gov

Participant flow15

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Phase Ib: DL 1	6
Overall Study	STARTED	Phase Ib: DL 2	7
Overall Study	STARTED	Phase Ib: DL 3	0
Overall Study	STARTED	Phase Ib: DL 4	0
Overall Study	STARTED	Phase IIa - MTD	14
Overall Study	COMPLETED	Phase Ib: DL 1	6
Overall Study	COMPLETED	Phase Ib: DL 2	6
Overall Study	COMPLETED	Phase Ib: DL 3	0
Overall Study	COMPLETED	Phase Ib: DL 4	0
Overall Study	COMPLETED	Phase IIa - MTD	12

1 to 10 of 15Source ClinicalTrials.gov

See all 15 participant flow

Adverse events125

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk
other	Anemia	Blood and lymphatic system disorders	Phase Ib: DL 1	0	6
other	Anemia	Blood and lymphatic system disorders	Phase Ib: DL 2	2	7
other	Anemia	Blood and lymphatic system disorders	Phase Ib: DL 3		0
other	Anemia	Blood and lymphatic system disorders	Phase Ib: DL 4		0
other	Anemia	Blood and lymphatic system disorders	Phase IIa - MTD	0	14
other	Platelet count decreased	Investigations	Phase Ib: DL 1	1	6
other	Platelet count decreased	Investigations	Phase Ib: DL 2	3	7
other	Platelet count decreased	Investigations	Phase Ib: DL 3		0
other	Platelet count decreased	Investigations	Phase Ib: DL 4		0
other	Platelet count decreased	Investigations	Phase IIa - MTD	2	14

1 to 10 of 125Source ClinicalTrials.gov

See all 125 adverse events

Adverse event totals15

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Phase Ib: DL 1	4	6
Total, all-cause mortality	Phase Ib: DL 2	6	7
Total, all-cause mortality	Phase Ib: DL 3	0	0
Total, all-cause mortality	Phase Ib: DL 4	0	0
Total, all-cause mortality	Phase IIa - MTD	8	14
Total, other adverse events	Phase Ib: DL 1	2	6
Total, other adverse events	Phase Ib: DL 2	6	7
Total, other adverse events	Phase Ib: DL 3	0	0
Total, other adverse events	Phase Ib: DL 4	0	0
Total, other adverse events	Phase IIa - MTD	5	14

1 to 10 of 15Source ClinicalTrials.gov

See all 15 adverse event totals

Papers0

The papers the trial lists on ClinicalTrials.gov.

None in this release.

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT02341014

GET https://conductscience.org/api/trials/v1/NCT02341014/events?page=2

API reference For AI assistants